June 6, 2017
Novo Nordisk to sell its haemophilia B drug in EU
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: haemophilia B
February 16, 2017
Sobi expands haemophilia B development portfolio
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.